Beschreibung:
<jats:sec><jats:title>Aims</jats:title><jats:p>The aim was to describe the utilization of antidiabetic agents, in terms of persistence and regimen change, in the management of a cohort of newly treated type 2 diabetes patients and to investigate associated socio‐demographic and treatment factors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A population‐based retrospective cohort study was conducted using the national pharmacy claims database in <jats:styled-content style="fixed-case">I</jats:styled-content>reland. Subjects were analyzed for persistence and regimen change. Cox proportional hazards regression examined associations of socio‐demographic and treatment factors on treatment patterns. Hazard ratios (<jats:styled-content style="fixed-case">HR</jats:styled-content>) and 95% <jats:styled-content style="fixed-case">CIs</jats:styled-content> are presented.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 20947 subjects were identified in the study over a 2 year period. Most were initiated on metformin (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non‐persistence was significantly lower in the youngest (40–49 years) age groups (reference 60–69 years) (<jats:styled-content style="fixed-case">HR</jats:styled-content> 1.62, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> 1.42, 1.84) and those on sulphonylureas (<jats:styled-content style="fixed-case">HR</jats:styled-content> 1.49, 95% CI 1.36, 1.64). The likelihood of receiving a regimen change was significantly lower in the older (80+ years) age groups (<jats:styled-content style="fixed-case">HR</jats:styled-content> 0.63, 95% CI 0.56, 0.71), females (<jats:styled-content style="fixed-case">HR</jats:styled-content> 0.91, 95% CI 0.86, 0.95), and those with pre‐existing <jats:styled-content style="fixed-case">CVD</jats:styled-content> (1 <jats:italic>vs</jats:italic>. 0 <jats:styled-content style="fixed-case">CVD</jats:styled-content> medicines) (<jats:styled-content style="fixed-case">HR</jats:styled-content> 0.82, 95% CI 0.74, 0.90), and higher in those on sulphonylureas (<jats:styled-content style="fixed-case">HR</jats:styled-content> 1.83, 95% CI 1.73, 1.94).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Type of treatment, pre‐existing <jats:styled-content style="fixed-case">CVD</jats:styled-content> and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimization of initial and subsequent antidiabetic agent prescribing may be possible.</jats:p></jats:sec>